Literature DB >> 7693853

Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells.

H Tilg1, E Vannier, G Vachino, C A Dinarello, J W Mier.   

Abstract

This study was undertaken to determine whether acute phase proteins (APP) induce the synthesis of interleukin 1 beta (IL-1 beta) and its specific antagonist, IL-1 receptor antagonist (IL-1Ra), in human peripheral blood mononuclear cells (PBMC). PBMC from healthy volunteers were incubated with C-reactive protein (CRP), alpha 1-antitrypsin (alpha 1-AT), or alpha 1-acid glycoprotein (AGP), and the levels of IL-1 beta and IL-1Ra produced were measured by specific radioimmunoassay. To evaluate the effects of alpha 1-AT further, a synthetic pentapeptide FVYLI corresponding to the minimal binding sequence for the serpine-enzyme complex receptor was also evaluated. PBMC incubated for 24 h with CRP, alpha 1-AT, or the pentapeptide FVYLI synthesized large quantities of IL-1Ra, 5-10-fold greater than the amount of IL-1 beta produced by these cells. AGP induced significantly less IL-1Ra than the other APP tested. These effects were shown to be specific, in that polyclonal antibodies against CRP, alpha 1-AT, and AGP eliminated the cytokine production induced by these respective proteins. CRP, alpha 1-AT, FVYLI, and AGP were synergistic with low concentrations of endotoxin in the induction of both IL-1Ra and IL-1 beta synthesis. We suggest that the preferential induction of IL-1Ra by APP may contribute to their antiinflammatory effects and provide an important regulatory signal for the acute phase response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693853      PMCID: PMC2191253          DOI: 10.1084/jem.178.5.1629

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Release of elastase from monocytes adherent to a fibronectin-gelatin surface.

Authors:  D L Xie; R Meyers; G A Homandberg
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

2.  Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.

Authors:  P F Piguet; C Vesin; G E Grau; R C Thompson
Journal:  Cytokine       Date:  1993-01       Impact factor: 3.861

3.  C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages.

Authors:  B Galve-de Rochemonteix; K Wiktorowicz; I Kushner; J M Dayer
Journal:  J Leukoc Biol       Date:  1993-04       Impact factor: 4.962

4.  The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide.

Authors:  G Joslin; G L Griffin; A M August; S Adams; R J Fallon; R M Senior; D H Perlmutter
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

5.  Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes.

Authors:  L Kilpatrick; L McCawley; V Nachiappan; W Greer; S Majumdar; H M Korchak; S D Douglas
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

6.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein.

Authors:  S P Ballou; G Lozanski
Journal:  Cytokine       Date:  1992-09       Impact factor: 3.861

7.  Cross-competition for binding of alpha 1-antitrypsin (alpha 1 AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified alpha 1 AT.

Authors:  G Joslin; A Wittwer; S Adams; D M Tollefsen; A August; D H Perlmutter
Journal:  J Biol Chem       Date:  1993-01-25       Impact factor: 5.157

8.  Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis.

Authors:  R M Heuertz; C A Piquette; R O Webster
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

9.  Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin.

Authors:  N Bucurenci; D R Blake; K Chidwick; P G Winyard
Journal:  FEBS Lett       Date:  1992-03-23       Impact factor: 4.124

10.  Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera.

Authors:  T W De Graaf; M E Van der Stelt; M G Anbergen; W van Dijk
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

View more
  66 in total

1.  Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD.

Authors:  Sabine Geiger; Emrah I Ozay; Ulf Geumann; Marina K Hereth; Terese Magnusson; Sudarvili Shanthalingam; Daniela Hirsch; Stefanie Kälin; Christine Günther; Barbara A Osborne; Gregory N Tew; Felix G Hermann; Lisa M Minter
Journal:  Mol Ther       Date:  2019-05-16       Impact factor: 11.454

Review 2.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

3.  Expression of cyclooxygenase-2, alpha 1-acid-glycoprotein and inducible nitric oxide synthase in the developing lesions of murine leprosy.

Authors:  Mayra Silva Miranda; Kendy Wek Rodríguez; Erasmo Martínez Cordero; Oscar Rojas-Espinosa
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

4.  Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration.

Authors:  Mariam Al-Omari; Elena Korenbaum; Matthias Ballmaier; Ulrich Lehmann; Danny Jonigk; Dietmar J Manstein; Tobias Welte; Ravi Mahadeva; Sabina Janciauskiene
Journal:  Mol Med       Date:  2011-04-11       Impact factor: 6.354

Review 5.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

6.  The acute phase protein haptoglobin regulates host immunity.

Authors:  Kristin M Huntoon; Yanping Wang; Cheryl A Eppolito; Karen W Barbour; Franklin G Berger; Protul A Shrikant; Heinz Baumann
Journal:  J Leukoc Biol       Date:  2008-04-24       Impact factor: 4.962

7.  α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection.

Authors:  Galit Shahaf; Hadas Moser; Eyal Ozeri; Mark Mizrahi; Avishag Abecassis; Eli C Lewis
Journal:  Mol Med       Date:  2011-06-09       Impact factor: 6.354

8.  Alpha 1-antitrypsin therapy mitigated ischemic stroke damage in rats.

Authors:  Huong L Moldthan; Aaron C Hirko; Jeffrey S Thinschmidt; Maria B Grant; Zhimin Li; Joanna Peris; Yuanqing Lu; Ahmed S Elshikha; Michael A King; Jeffrey A Hughes; Sihong Song
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-02-28       Impact factor: 2.136

9.  alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.

Authors:  Eli C Lewis; Mark Mizrahi; Michel Toledano; Nathaniel Defelice; Joanne L Wright; Andrew Churg; Leland Shapiro; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

10.  α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide induced IL-1β in human blood neutrophils.

Authors:  Nupur Aggarwal; Elena Korenbaum; Ravi Mahadeva; Stephan Immenschuh; Veronika Grau; Charles A Dinarello; Tobias Welte; Sabina Janciauskiene
Journal:  Mol Med       Date:  2016-10-04       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.